Table 2 EC50 values across multiple CREB3L1-deficient TNBC and luminal A breast cancer cell lines.
Cell line | Palbociclib Isethionate | Cladribine | Lanatoside C | Homoharringtonine | ||||
|---|---|---|---|---|---|---|---|---|
Parental EC50, nM (na) | Parental + HA-CREB3L1 EC50, nM (na) | Parental EC50, nM (na) | Parental + HA-CREB3L1 EC50, nM (na) | Parental EC50, nM (na) | Parental + HA-CREB3L1 EC50, nM (na) | Parental EC50, nM (na) | Parental + HA-CREB3L1 EC50, nM (na) | |
BT549 | 12600 ± 4800 (9) |  | 178 ± 84 (9) |  | 42 ± 12 (9) |  | 89 ± 10 (9) |  |
HCC1395 | 4000 ± 2000 (6) |  | 10100 ± 1200 (6) |  | 510 ± 300 (6) |  | 104 ± 31 (6) |  |
HCC1806 | 500 ± 130 (9) | 1300 ± 490 (9) | 92 ± 44 (9) | 182 ± 60 (9) | 143 ± 85 (9) | 233 ± 100 (9) | 29 ± 4 (9) | 42 ± 7 (9) |
HCC38 | 210 ± 70 (9) |  | 65 ± 56 (9) |  | 300 ± 100 (9) |  | 58 ± 10 (9) |  |
Hs578T | 3200 ± 1400 (4) |  | 5700 ± 1200 (4) |  | 1000 ± 800 (4) |  | 42 ± 24 (4) |  |
MDA-MB-157 | ND |  | 5000 ± 4300 (4) |  | 550 ± 240 (4) |  | 7.5 ± 1.2 (4) |  |
MDA-MB-436 | 17000 ± 14000 (4) |  | 660 ± 180 (4) |  | 460 ± 250 (4) |  | 33 ± 36 (4) |  |
HCC1428 | 21 ± 15 (4) | 160 ± 250 (4) | 740 ± 330 (4) | 2200 ± 1700 (4) | 35 ± 8 (4) | 32 ± 8 (4) | 9 ± 3 (4) | 10 ± 3 (4) |
MCF7 | 4400 ± 3500 (4) |  | 3400 ± 2100 (4) |  | 450 ± 490 (4) |  | 18 ± 9 (4) |  |
T47D | 13000 ± 9800 (4) | 7200 ± 9200 (4) | 9600 ± 1800 (6) | 1800 ± 1300 (6) | 500 ± 50 (4) | 89 ± 34 (4) | 400 ± 180 (6) | 88 ± 55 (6) |
ZR-75-1 | 710 ± 350 (8) |  | 750 ± 350 (9) |  | 650 ± 510 (9) |  | 117 ± 35 (9) |  |
